Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEWELL-302: branchritinib versus best available therapy in hydroxyurea-resistant or -intolerant polycythemia vera
CTR20240873Phase 3Active
- Sponsor
- Huadong Medicine
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bezacitinib in polycythemia vera (PV), sponsored by Huadong Medicine. Started Jun 2024; status: active.
02
Drugs
bezacitinib
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on CTR20240873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240873.